Kawasaki disease in siblings and a review of drug treatment
subject: covid-19, intravenous immunoglobulin, kawasaki disease, Dipyridamole, Siblings
description: We have managed two anonymized siblings with Kawasaki disease (KD). The occurrence of KD in the elder brother alerted us to the occurrence of incomplete KD in the younger brother. Both siblings were treated with intravenous immunoglobulin and a high dose of dipyridamole with resolution of the coronary artery aneurysm. Dipyridamole was used instead of aspirin because both siblings were glucose-6-phosphate dehydrogenase deficient for which aspirin was contraindicated. To prevent damage to the coronary arteries, treatment should be started as soon as the diagnosis is made. There have been a lot of advances in medical therapy in recent years, which are reviewed together with conventional proven therapy for KD. Early diagnosis and prompt treatment are important to achieve optimal treatment outcome in KD. Family history of KD among siblings enables clinicians for an earlier diagnosis so as to prevent the disease complications particularly in patients with incomplete features.
creator: Steven King-fan Loo, Kam Lun Hon, Alexander KC Leung, Tak Cheung Yung, Man Ching Yam
source: Drugs in Context
publisher: BioExcel Publishing Ltd
date: 2020
coverage: Therapeutics. Pharmacology